NATCOPHARM vs SHILPAMED: Stock Comparison
SHILPA MEDICARE is the larger company by market capitalisation. NATCO PHARMA shows a lower P/E, a higher ROE and a higher dividend yield, while SHILPA MEDICARE shows faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NATCOPHARM leads 8; SHILPAMED leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NATCOPHARM | SHILPAMED |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NATCOPHARM | SHILPAMED |
|---|---|---|
| Live Price | ₹791.8 | ₹931.7 |
| Day Change | 0.54% | -0.42% |
| Volume | 58,413 | 2.91 L |
| 52-Week High | ₹1,226.8 | ₹1,095 |
| 52-Week Low | ₹773.6 | ₹259.5 |
| Distance from 52W High | -35.46% | -14.91% |
Valuation
| Metric | NATCOPHARM | SHILPAMED |
|---|---|---|
| Market Cap | ₹15,532 Cr | ₹18,776 Cr |
| P/E Ratio | 13.49x | 61.4x |
| P/B Ratio | 1.67x | 7.04x |
| EPS | ₹10.53 | ₹5.16 |
| Book Value | ₹470.06 | ₹132.49 |
| Dividend Yield | 0.57% | 0.06% |
Growth
| Metric | NATCOPHARM | SHILPAMED |
|---|---|---|
| Revenue Growth (TTM YoY) | -39.6% | 31.5% |
| EPS Growth (TTM YoY) | -34.1% | 644.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | NATCOPHARM | SHILPAMED |
|---|---|---|
| ROE | 14.98% | 5.1% |
| ROCE | 15.1% | 5.31% |
| Net Margin | 34.78% | 15.82% |
| Operating Margin | 38.85% | 27.86% |
| Debt to Equity | 0.08x | 0.05x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | NATCOPHARM | SHILPAMED |
|---|---|---|
| Promoter Holding | 49.12%▼ 0.02 pp | 40.13% |
| FII Holding | 16%▼ 0.99 pp | 12.11%▲ 0.73 pp |
| DII Holding | 6.16%▲ 0.54 pp | 8.26%▲ 0.21 pp |
| Public Holding | 28.45%▲ 0.48 pp | 39.49%▼ 0.94 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NATCO PHARMA and SHILPA MEDICARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.